In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
A: According to FDA prescribing information and clinical trial data, the most common side effects are gastrointestinal: Nausea : 20-44% of users (most common) Diarrhea : ~30% of users Constipation : 24-30% of users Vomiting : 9-24% of users Abdominal pain : 10-20% of users Side effects are typically most intense during first 1-2 weeks at a new dose level and improve significantly by weeks 3-4 at steady dosing
Here is how to handle the most common problems researchers encounter
Patient satisfaction surveys and retention data from both platforms, compiled from multiple review sources including Trustpilot and Google Reviews, March 2026
Thats because being in a calorie deficit forces your body to break down stored body fat (vs
Umbrella Labs positions retatrutide for this type of work by emphasizing stable specifications, traceability, and documentation readiness that aligns to high rigor bench science
,aspect=ignore)
,aspect=ignore)
,aspect=ignore)
